Consensus guidelines for warfarin therapy: Recommendations from the Australasian society of thrombosis and haemostasis

Alex S. Gallus, Ross I. Baker, Beng H. Chong, Paul A. Ockelford, Alison M. Street

Research output: Contribution to journalReview articlepeer-review

101 Citations (Scopus)

Abstract

The anticoagulant effect of warfarin should be kept at an international normalised ratio (INR) of about 2.5 (desirable range, 2.0-3.0), although a higher level may be better in a few clinical conditions. The risk of bleeding increases exponentially with INR and becomes clinically unacceptable once the INR exceeds 5.0. Warfarin therapy should be continued for around six weeks for symptomatic calf vein thrombosis, and for 3-6 months after proximal deep vein thrombosis (DVT) that occurs after surgery or limited medical illness. Therapy for six months or longer could be considered for DVT occurring without an obvious precipitating factor, proven recurrent venous thromboembolism (VTE), or if there are continuing risk factors. Oral anticoagulants prevent ischaemic stroke in atrial fibrillation (AF). Maximum efficacy requires an INR >2.0, but some benefit remains at an INR of 1.5-1.9. Patients aged over 75 years are at greatest risk of intracranial bleeding during warfarin therapy for AF, and the target INR may be reduced to 2.0-2.5, or perhaps as low as 1.5-2.0, in such patients. Warfarin should be withheld if it is more likely to cause major bleeding than to protect from stroke (eg, in young people with isolated AF where the annual baseline risk of stroke is < 1%). In patients with AF, aspirin is less effective than warfarin (much less effective after such patients have had a stroke or transient cerebral ischaemia). In people with prosthetic heart valves, an INR of 2.5-3.5 is probably sufficient for bileaflet or tilting disc valves, but a higher target INR is necessary for caged ball or caged disc valves. The addition of aspirin (100 mg/day) further decreases the risk of embolism but increases the risk of gastrointestinal bleeding.

Original languageEnglish
Pages (from-to)600-605
Number of pages6
JournalMedical Journal of Australia
Volume172
Issue number12
DOIs
Publication statusPublished - 19 Jun 2000
Externally publishedYes

Fingerprint Dive into the research topics of 'Consensus guidelines for warfarin therapy: Recommendations from the Australasian society of thrombosis and haemostasis'. Together they form a unique fingerprint.

Cite this